Invitrogen Inks Deal with WARF to Develop hESCs for Research Applications | GenomeWeb
NEW YORK (GenomeWeb News) - Invitrogen said today that it has licensed intellectual property from the Wisconsin Alumni Research Foundation that will enable it to develop research tools using human embryonic stem cells.
 
Under the terms of the agreement, the licensing organization for the University of Wisconsin-Madison has granted Invitrogen the right to work with karyotypically normal hESCs to develop research and drug discovery tools.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.